Wang Yuli, Yang Jiahui, Qian Yong, Yang Meiyan, Qiu Yan, Huang Wei, Shan Li, Gao Chunsheng
Department of Pharmaceutics, Beijing Institute of Pharmacology and Toxicology , Beijing , P.R. China .
Drug Dev Ind Pharm. 2015;41(7):1120-9. doi: 10.3109/03639045.2014.931969. Epub 2014 Jul 1.
The objective of this study was to develop a novel ethylcellulose (EC)-coated pellet with partial active dose as a pore former for the controlled release of water-soluble metoprolol succinate (MS) without an initial lag phase (slow/non-drug release phase). MS-layered cores with a high drug-loading efficiency (97%, w/w), a smooth surface, and an acceptable level of resistance to abrasion were first obtained by spraying a concentrated drug solution (60% w/w at 70 °C) on non-pareils in the absence of other binders. The presence of the drug in an EC coating solution significantly improved the coating process by reducing pellet stickiness. Central composite design and response surface methodology was employed to optimize and explore the effect of pore former MS level (X1) and EC coating level (X2) on the drug release. The pore former level had a positive effect on the MS release and the coating level had a negative effect. The level of X1 and X2 of the optimization were 17% and 23%, respectively, and the cumulative percent of MS released within 1 h was up to 9.2%. Accordingly, the initial lag phase associated with in vitro drug release from EC-coated pellets was absent when MS drug was used as a pore former, which was further confirmed by in vivo drug release in beagle dogs. Thus, a novel approach for the controlled release of MS from coated pellets without lag phase has been successfully developed, which is valuable for the advancement of sustained-release pellets.
本研究的目的是开发一种新型的乙基纤维素(EC)包衣微丸,其含有部分活性剂量作为致孔剂,用于水溶性琥珀酸美托洛尔(MS)的控释,且无初始滞后阶段(缓慢/无药物释放阶段)。首先,通过在不存在其他粘合剂的情况下,将浓药物溶液(70℃时60% w/w)喷洒在非pareil微丸上,获得了具有高载药效率(97%,w/w)、光滑表面和可接受耐磨水平的MS层芯。EC包衣溶液中药物的存在通过降低微丸粘性显著改善了包衣过程。采用中心复合设计和响应面方法来优化和探究致孔剂MS水平(X1)和EC包衣水平(X2)对药物释放的影响。致孔剂水平对MS释放有积极影响,包衣水平有消极影响。优化后的X1和X2水平分别为17%和23%,1小时内MS释放的累积百分比高达9.2%。因此,当将MS药物用作致孔剂时,与EC包衣微丸体外药物释放相关的初始滞后阶段不存在,这在比格犬体内药物释放中得到了进一步证实。因此,已成功开发出一种从包衣微丸中无滞后阶段控释MS的新方法,这对缓释微丸的发展具有重要价值。